PMC:7195088 / 18991-19173 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"665","span":{"begin":30,"end":38},"obj":"Species"},{"id":"772","span":{"begin":5,"end":13},"obj":"Chemical"},{"id":"926","span":{"begin":44,"end":52},"obj":"Disease"},{"id":"927","span":{"begin":140,"end":148},"obj":"Disease"}],"attributes":[{"id":"A665","pred":"tao:has_database_id","subj":"665","obj":"Tax:9606"},{"id":"A772","pred":"tao:has_database_id","subj":"772","obj":"MESH:D019808"},{"id":"A926","pred":"tao:has_database_id","subj":"926","obj":"MESH:C000657245"},{"id":"A927","pred":"tao:has_database_id","subj":"927","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":" vs. losartan vs. placebos in patients with COVID-19. Double-blind, adaptive RCT (NCT04328012, not yet recruiting). Primary endpoint: NIAID COVID-19 ordinal severity scale (follow-up"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T9","span":{"begin":166,"end":171},"obj":"Body_part"}],"attributes":[{"id":"A9","pred":"uberon_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/UBERON_0002542"}],"text":" vs. losartan vs. placebos in patients with COVID-19. Double-blind, adaptive RCT (NCT04328012, not yet recruiting). Primary endpoint: NIAID COVID-19 ordinal severity scale (follow-up"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T93","span":{"begin":44,"end":52},"obj":"Disease"},{"id":"T94","span":{"begin":140,"end":148},"obj":"Disease"}],"attributes":[{"id":"A93","pred":"mondo_id","subj":"T93","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A94","pred":"mondo_id","subj":"T94","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":" vs. losartan vs. placebos in patients with COVID-19. Double-blind, adaptive RCT (NCT04328012, not yet recruiting). Primary endpoint: NIAID COVID-19 ordinal severity scale (follow-up"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T176","span":{"begin":5,"end":13},"obj":"Chemical"}],"attributes":[{"id":"A176","pred":"chebi_id","subj":"T176","obj":"http://purl.obolibrary.org/obo/CHEBI_6541"}],"text":" vs. losartan vs. placebos in patients with COVID-19. Double-blind, adaptive RCT (NCT04328012, not yet recruiting). Primary endpoint: NIAID COVID-19 ordinal severity scale (follow-up"}

{"project":"LitCovid-sentences","denotations":[{"id":"T130","span":{"begin":54,"end":115},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":" vs. losartan vs. placebos in patients with COVID-19. Double-blind, adaptive RCT (NCT04328012, not yet recruiting). Primary endpoint: NIAID COVID-19 ordinal severity scale (follow-up"}